Hydroxychloroquine

Generic Name
Hydroxychloroquine
Brand Names
Plaquenil, Sovuna
Drug Type
Small Molecule
Chemical Formula
C18H26ClN3O
CAS Number
118-42-3
Unique Ingredient Identifier
4QWG6N8QKH
Background

Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...

Indication

Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.

Associated Conditions
Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
Associated Therapies
-
Clinical Trials
Related News

The Clinical Efficacy of Immunomodulators in RA Patients

First Posted Date
2022-11-23
Last Posted Date
2022-11-29
Lead Sponsor
Qilu Hospital of Shandong University
Target Recruit Count
400
Registration Number
NCT05626348
Locations
🇨🇳

Qilu Hospital, Jinan, Shandong, China

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Phase 2
Recruiting
Conditions
Pancreatic Cancer
Interventions
Drug: Trametinib
Drug: Hydroxychloroquine
First Posted Date
2022-08-26
Last Posted Date
2023-06-18
Lead Sponsor
Cancer Trials Ireland
Target Recruit Count
22
Registration Number
NCT05518110
Locations
🇮🇪

Mater Misericordiae University Hospital, Dublin, Ireland

🇮🇪

St Vincent's University Hospital, Dublin, Ireland

The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia

Phase 3
Recruiting
Conditions
Preeclampsia
Interventions
Drug: Hydroxychloroquine
First Posted Date
2022-03-18
Last Posted Date
2023-11-28
Lead Sponsor
Yoo-min Kim
Target Recruit Count
58
Registration Number
NCT05287321
Locations
🇰🇷

Chung-Ang University Hospital, Seoul, Korea, Republic of

Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss

First Posted Date
2022-02-14
Last Posted Date
2022-02-14
Lead Sponsor
Ain Shams University
Target Recruit Count
70
Registration Number
NCT05237843

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

First Posted Date
2022-02-02
Last Posted Date
2024-07-22
Lead Sponsor
BioMed Valley Discoveries, Inc
Target Recruit Count
47
Registration Number
NCT05221320
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

University of California San Francisco, San Francisco, California, United States

and more 6 locations

Hydroxychloroquine in Mild Graves' Orbitopathy

Phase 4
Recruiting
Conditions
Graves Ophthalmopathy
Interventions
Drug: Hydroxychloroquine
First Posted Date
2021-11-18
Last Posted Date
2024-01-17
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
108
Registration Number
NCT05126147
Locations
🇨🇳

National Taiwan University Hospital, Hsin-Chu branch, Hsinchu, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

Phase 1
Active, not recruiting
Conditions
Ulcerative Colitis (Disorder)
Interventions
Drug: Hydroxychloroquine
Drug: Mesalamine
First Posted Date
2021-11-12
Last Posted Date
2024-03-04
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
20
Registration Number
NCT05119140
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital, New York, New York, United States

🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

The Danish Pre-HCQ COVID Dialysis Study

Phase 4
Withdrawn
Conditions
COVID-19
End Stage Renal Disease
Interventions
Drug: Hydroxychloroquine
First Posted Date
2021-11-08
Last Posted Date
2021-11-08
Lead Sponsor
Nicholas Carlson
Registration Number
NCT05110651
Locations
🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇩🇰

Herlev Hospital, Herlev, Denmark

🇩🇰

North Zealand Hospital, Hillerød, Denmark

Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients

Phase 2
Conditions
Mastocytosis
Interventions
Drug: Hydroxychloroquine
First Posted Date
2021-10-20
Last Posted Date
2021-10-20
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
30
Registration Number
NCT05084872
Locations
🇫🇷

Larrey Hospital - Toulouse University Hospital, Toulouse, France

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

First Posted Date
2021-09-13
Last Posted Date
2024-10-28
Lead Sponsor
University of Oxford
Target Recruit Count
3800
Registration Number
NCT05041907
Locations
🇳🇵

Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal

🇧🇷

Universidade Federal de Minas Gerais, Minas Gerais, Brazil

🇱🇦

Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy